Physician profile
Nathan Farley
NPI 1427476035
$12,200.37
in general payments reported to CMS, 2019-2025
15 companies · $911 in 2025
The $911 reported for 2025 was more than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,986 · 2020: $4,987 · 2021: $98.29 · 2022: $858 · 2023: $1,189 · 2024: $2,172 · 2025: $911.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,272.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,271.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $3,835.87 | 2019-2025 | Susvimo, Vabysmo |
| Alimera Sciences, INC. | $3,674.18 | 2019-2024 | Iluvien, Yutiq |
| Novartis Pharmaceuticals Corporation | $1,452.64 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $1,222.94 | 2019-2025 | Eylea Hd, Eylea |
| Regeneron Pharmaceuticals, INC. | $921.32 | 2019 | |
| Ani Pharmaceuticals, INC. | $269.70 | 2025 | Iluvien, Yutiq, Purified Cortrophin Gel |
| Apellis Pharmaceuticals, INC. | $234.50 | 2022-2025 | Syfovre |
| Astellas Pharma US INC | $136.20 | 2024-2025 | Izervay |
| Allergan, INC. | $132.24 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $102.23 | 2022-2025 | Xipere |
| Eyepoint US, INC. | $78.33 | 2019-2023 | |
| Alcon Vision LLC | $55.46 | 2019 | |
| Abbvie INC. | $38.38 | 2022 | |
| Biogen, INC. | $37.51 | 2023-2024 | Byooviz |
| Oculus Surgical INC. | $8.87 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Farley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.